Page 8 - Read Online

38 Tumor heterogeneity and therapy resistance - implications for future treatments of prostate
cancer
Fiona M. Frame, Amanda R. Noble, Sandra Klein, Hannah F. Walker, Rakesh Suman, Richard
Kasprowicz, Vin M. Mann, Matt S. Simms, Norman J. Maitland
J Cancer Metastasis Treat 2017;3:302-14 http://dx.doi.org/10.20517/2394-4722.2017.34

39 Membrane-type matrix metalloproteinases: expression, roles in metastatic prostate cancer
progression and opportunities for drug targeting
Robert A. Falconer, Paul M. Loadman
J Cancer Metastasis Treat 2017;3:315-327 http://dx.doi.org/10.20517/2394-4722.2017.40

40 Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for
therapeutic intervention
Agnese C. Pippione, Donatella Boschi, Klaus Pors, Simonetta Oliaro-Bosso, Marco L. Lolli
J Cancer Metastasis Treat 2017;3:328-361 http://dx.doi.org/10.20517/2394-4722.2017.44

41 Treatment of liver metastases in patients selected for cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis
Antonio Sommariva
J Cancer Metastasis Treat 2017;3:362-367 http://dx.doi.org/10.20517/2394-4722.2017.37